“The LiPlasome drug delivery technology hides the active drugs in lipids, goes via the blood system and targets, penetrates and destroys the malign tumor cells”

Palle Schelde, CEO

Targeted Lipid Technology

The combination of a protected blood transporting nanocarrier system and a specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems (DDS) will gain increasing importance in the coming years.

LiPlasome Pharma’s proprietary drug delivery technology represents a spin-off from fundamental research carried out by the founders of the company over the last decade.